Drug intelligence / Profile preview

crotoeurin B

Development stage: Preclinical
Modality: Small Molecules

Overview

Crotoeurin B is a clerodane diterpenoid isolated from the leaves and twigs of *Croton lachnocarpus Benth.*. It has demonstrated dopaminergic neuroprotective activity, specifically alleviating dopaminergic neuron degeneration in a transgenic *Caenorhabditis elegans* pathological model induced by 6-hydroxydopamine (6-OHDA). This activity suggests its potential as a therapeutic agent for Parkinson's disease.

Beyond the preview

Go deeper on crotoeurin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on crotoeurin B.

Explore the full profile